Fangzhou Inc.’s H2H Smart Healthcare Platform Honored as one of Guangdong’s Premier High-Tech Innovation Products

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

GUANGZHOU, China, March 17, 2025 /PRNewswire/ — Fangzhou Inc. (“Fangzhou” or the “Company”) (06086.HK), a leader in Internet healthcare solutions, today announced that its proprietary “H2H Smart Healthcare Innovation Platform” has been distinguished as a “2024 Guangdong Province Premier High-Quality and High-Tech Product” by the Guangdong High-Tech Industry Association. This prestigious accolade underscores Fangzhou’s pioneering advancements in technological innovation and leadership in shaping the digital healthcare landscape.

Dr. Xie Fangmin, founder, chairman, and CEO of Fangzhou, commented, “The H2H platform’s inclusion highlights our role in advancing smart healthcare through groundbreaking solutions. Fangzhou looks forward to advancing the Internet healthcare sector toward sustainable and high-impact growth, by intensifying focus on AI-driven healthcare ecosystems, fostering deeper relationships with industry stakeholders.”

Pursuing Innovation in AI-Powered Healthcare

Fangzhou continues to push the boundaries of technological excellence. In 2025, the Company successfully deployed cutting-edge AI models, leveraging DeepSeek-V3 and DeepSeek-R1, through full-scale integration and local deployment. Through its strategic collaboration with Tencent Cloud and Tencent Health, Fangzhou is exploring transformative AI applications across pharmaceutical logistics and healthcare services.

AI Assisted Healthcare

By harnessing its “AI + H2H Smart Healthcare Ecosystem”, Fangzhou’s upgraded platform now features four flagship AI-driven modules: AI Physician Assistant, AI Customer Engagement Assistant, AI Procurement Orchestrator, and AI Content Assistant. We believe that these AI enabled applications have the potential significantly enhance efficiency across our platform, ultimately enabling us to deliver an improved user experience for our patients and customers.

About Fangzhou Inc.

Fangzhou Inc. (06086.HK) is China’s leading online chronic disease management platform. With 45.6 million registered users and 217,000 registered doctors on its platform (as of June 30, 2024), the Company provides tailored medical care and precision medicine for a growing population of chronic disease patients. For more details, visit https://investors.jianke.com.

About the “Guangdong Province Premier High-Quality and High-Tech Product” Award

The “Guangdong Province Premier High-Quality and High-Tech Product” designation celebrates innovations developed by local high-tech enterprises that exemplify proprietary intellectual property, technological sophistication, market leadership, and disruptive potential. Rigorously evaluated by industry experts, award-winning products embody Guangdong’s commitment to fostering a globally competitive innovation ecosystem and driving economic advancement through technological leadership.

Media Contact

For further inquiries or interviews, please reach out to:

Xingwei Zhao Associate Director of Public Relations Email: pr@jianke.com 

Disclaimer: This press release contains forward-looking statements. Actual results may differ materially from those anticipated due to various factors. Readers are cautioned not to place undue reliance on these statements

View original content to download multimedia:https://www.prnewswire.com/news-releases/fangzhou-incs-h2h-smart-healthcare-platform-honored-as-one-of-guangdongs-premier-high-tech-innovation-products-302402882.html

SOURCE Fangzhou Inc.

Staff

Recent Posts

Solventum partners with SprintRay to disrupt the digital dentistry market with high-quality, permanent same-day restorations

In this first-of-its-kind partnership for its Dental Solutions business, Solventum, formerly 3M Health Care, is…

55 minutes ago

Health in Tech Expands Access to Virtual Care Through Collaboration with DialCare

STUART, Fla., March 25, 2025 /PRNewswire/ -- Health In Tech (Nasdaq: HIT), an Insurtech platform…

7 hours ago

Concord Orthopaedic Notifies Individuals of Security Incident

CONCORD, N.H., March 25, 2025 /PRNewswire/ -- Concord Orthopaedic ("COPA") is an orthopedic clinic located…

7 hours ago

Mitolyn Brand Takes Legal Action Against Third-Party Sellers for Misinformation

HAMPTON, Va., March 25, 2025 /PRNewswire/ -- Bioventra, the parent company and official manufacturer of Mitolyn,…

7 hours ago

THE MOM’S CHOICE AWARDS NAMES AI-POWERED PREGNANCY & BABY WELLNESS WEARABLE ‘ELORA’ AMONG THE BEST IN FAMILY-FRIENDLY PRODUCTS

DOVER, Del., March 25, 2025 /PRNewswire/ -- The Mom's Choice Awards® has named Elora*, from leading…

7 hours ago

Paving the Way for Early Esophageal Cancer Detection:

New Sampling Technique Further Optimizes WATS3D Test Quality SUFFERN, N.Y., March 25, 2025 /PRNewswire/ -- CDx…

7 hours ago